Lexicon Pharmaceuticals (LXRX) Assets Average (2011 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Assets Average of $226.9 million for Q1 2026, down 23.87% year-over-year from $298.0 million in Q1 2025, and up 16.09% quarter-over-quarter from $195.5 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Assets Average (2011 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Assets Average for 16 consecutive years, with $226.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 23.87% year-over-year to $226.9 million; the TTM figure through Mar 2026 stood at $226.9 million (down 23.87% YoY), while the FY2025 annual figure was $241.7 million, down 8.42% from the prior year.
- Assets Average grew to $226.9 million in Q1 2026 per LXRX's latest filing, from $195.5 million in the prior quarter.
- Across five years, Assets Average topped out at $395.3 million in Q2 2024 and bottomed at $124.3 million in Q2 2022.
- Historically, Assets Average has averaged $243.9 million across 5 years, with a median of $239.7 million in 2023.
- Annual changes were most pronounced in 2023 — Assets Average surged 95.13% — and 2025, when it tumbled 37.87%.
- Lexicon Pharmaceuticals' Assets Average stood at $193.0 million in 2022, then soared by 31.07% to $253.0 million in 2023, then gained by 22.46% to $309.8 million in 2024, then tumbled by 36.9% to $195.5 million in 2025, then gained by 16.09% to $226.9 million in 2026.
- Business Quant data shows LXRX's Assets Average at $226.9 million in Q1 2026, $195.5 million in Q4 2025, and $215.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 259.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 259.44 Mn |
| Mar 31, 2026 | 226.90 Mn |
| Dec 31, 2025 | 195.46 Mn |
| Sep 30, 2025 | 215.76 Mn |
| Jun 30, 2025 | 261.63 Mn |
| Mar 31, 2025 | 298.05 Mn |
| Dec 31, 2024 | 309.77 Mn |
| Sep 30, 2024 | 347.24 Mn |
| Jun 30, 2024 | 395.29 Mn |
| Mar 31, 2024 | 323.32 Mn |
| Dec 31, 2023 | 252.95 Mn |
| Sep 30, 2023 | 296.60 Mn |
| Jun 30, 2023 | 239.72 Mn |
| Mar 31, 2023 | 178.51 Mn |
| Dec 31, 2022 | 192.99 Mn |
| Sep 30, 2022 | 152.01 Mn |
| Jun 30, 2022 | 124.25 Mn |
| Mar 31, 2022 | 136.54 Mn |
| Dec 31, 2021 | 154.62 Mn |
| Sep 30, 2021 | 172.00 Mn |